Targeted binding agents against b7-h1

Agents de liaison ciblés dirigés contre b7-h1

Abstract

L'invention concerne des anticorps monoclonaux humains dirigés contre B7-H1 et les utilisations de ces anticorps pour le diagnostic et pour le traitement de maladies associées à l'activité et/ou à l'expression de B7-H1. De plus, l'invention concerne des hybridomes ou d'autres lignées cellulaires exprimant de tels anticorps.
Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (2)

    Publication numberPublication dateAssigneeTitle
    US-2005226883-A1October 13, 2005Paul Averback, Jack GemmellHumanized antibody
    US-2009055944-A1February 26, 2009Medarex, Inc.Human monoclonal antibodies to be programmed death ligand 1 (pd-l1)

NO-Patent Citations (6)

    Title
    LI ET AL.: "Anti-Programmed Death-1 Synergized with Granulocyte Macrophage Colony- Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors", CLINICAL CANCER RESEARCH, vol. 15, no. 5, March 2009 (2009-03-01), pages 1623 - 1634, XP055166457, DOI: doi:10.1158/1078-0432.CCR-08-1825
    LIN ET AL.: "The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors", PNAS, vol. 105, no. 8, 26 February 2008 (2008-02-26), USA, pages 3011 - 3016, XP002683218, DOI: doi:10.1073/PNAS.0712278105
    LIN, D ET AL., PROC. NATL. ACAD. SCI. USA, vol. 105, 2008, pages 3011 - 3016
    NOMI ET AL.: "Clinical Significance and Therapeutic Potential of the Programmed Death-1 Pathway in Human Pancreatic Cancer", CLINICAL CANCER RESEARCH, vol. 13, 2007, pages 2151 - 2157, XP002533527, DOI: doi:10.1158/1078-0432.CCR-06-2746
    See also references of EP 2504364A4
    STROME ET AL.: "B7-H1 Blockade Augments Adoptive t-Cell Immunotherapy for Squamous Cell Carcinoma", CANCER RESEARCH, vol. 63, 2003, pages 6501 - 6505, XP002487684

Cited By (84)

    Publication numberPublication dateAssigneeTitle
    WO-2017153433-A1September 14, 2017Innate PharmaSiglec neutralizing antibodies
    WO-2017106656-A1June 22, 2017Novartis AgMolécules d'anticorps anti-pd-1 et leurs utilisations
    WO-2015033303-A1March 12, 2015Aurigene Discovery Technologies LimitedCyclic peptidomimetic compounds as immunomodulators
    WO-2016094481-A1June 16, 2016Regeneron Pharmaceuticals, Inc.Animaux non-humains présentant un groupe de gène groupe de différenciation 274 humanisé
    WO-2016146259-A1September 22, 2016Amal Therapeutics SaNouveau complexe comprenant un peptide pénétrant dans les cellules, une charge et un agoniste peptidique de tlr pour le traitement d'un glioblastome
    US-9815898-B2November 14, 2017Novartis Ag, President And Fellows Of Harvard College, Dana-Farber Cancer Institute, Inc.Antibody molecules to PD-1 and uses thereof
    WO-2016196298-A1December 08, 2016Genentech, Inc., F. Hoffmann-La Roche AgMéthodes diagnostiques et thérapeutiques pour le cancer
    WO-2016034718-A1March 10, 2016Medimmune LimitedMethods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma)
    WO-2015095418-A1June 25, 2015Genentech, Inc., F. Hoffmann-La Roche AgMethods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
    WO-2016201425-A1December 15, 2016Bristol-Myers Squibb CompanyTraitement du cancer par le blocage combiné des voies de signalisation pd-1 et cxcr4
    WO-2017004016-A1January 05, 2017The Rockefeller University, Bristol-Myers Squibb CompanyAnticorps anti-cd40 présentant une activité agoniste renforcée
    US-9828434-B2November 28, 2017Dana-Farber Cancer Institute, Inc.Human monoclonal anti-PD-L1 antibodies and methods of use
    US-9884913-B2February 06, 2018Novartis Ag, Dana-Farber Cancer Insititute, Inc., Children's Medical Center CorporationAntibody molecules to TIM-3 and uses thereof
    WO-2017019894-A1February 02, 2017Novartis Ag, Immutep S.A.SPolythérapies comprenant des molécules d'anticorps dirigées contre lag-3
    WO-2016081748-A2May 26, 2016Bristol-Myers Squibb CompanyAnticorps anti-cd73 et leurs utilisations
    WO-2014055648-A1April 10, 2014Bristol-Myers Squibb CompanyCombinaison d'anticorps anti-kir et d'anticorps anti-pd-1 pour le traitement du cancer
    WO-2015036499-A1March 19, 2015Medimmune LimitedAnticorps anti-b7-h1 destinés au traitement de tumeurs
    WO-2016127052-A1August 11, 2016Bristol-Myers Squibb Company, Providence Health & ServicesCxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
    US-9605070-B2March 28, 2017Novartis Ag, Dana-Farber Cancer Institute, Inc., Children's Medical Center CorporationAntibody molecules to TIM-3 and uses thereof
    WO-2015016718-A1February 05, 2015Bionovion Holding B.V.Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
    US-9789183-B1October 17, 2017Agency For Science, Technology And ResearchAnti-PD-L1 antibodies
    WO-2017118634-A1July 13, 2017INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Descartes, Assistance Publique-Hôpitaux De Paris (Aphp)Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
    WO-2016030455-A1March 03, 2016Medimmune LimitedAnticorps anti-b7-h1 et anti-ctla -4 pour le traitement du cancer du poumon non à petites cellules
    WO-2017184619-A2October 26, 2017Celldex Therapeutics, Inc.Agonistic antibodies that bind human cd40 and uses thereof
    US-9771338-B2September 26, 2017Auirgene Discovery Technologies Limited1,2,4-oxadiazole derivatives as immunomodulators
    WO-2016205320-A1December 22, 2016Genentech, Inc., F. Hoffmann-La Roche AgProcédés de traitement de cancers du sein métastatiques ou à un stade localement avancé à l'aide d'antagonistes se liant à l'axe pd-1 et de taxanes
    WO-2017087678-A2May 26, 2017Bristol-Myers Squibb CompanyAntibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
    WO-2013079174-A1June 06, 2013Merck Patent GmbhAnti-pd-l1 antibodies and uses thereof
    WO-2017019897-A1February 02, 2017Novartis Ag, Dana-Farber Cancer Institute, Inc., Children's Medical Center CorporationPolythérapies comprenant des molécules d'anticorps contre tim -3
    US-2016031990-A1February 04, 2016Medlmmune, LlcAntagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
    WO-2015095410-A1June 25, 2015Genentech, Inc., F. Hoffmann-La Roche AgMethods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
    WO-2016011160-A1January 21, 2016Genentech, Inc., F.Hoffman-La Roche AgCompositions de traitement du cancer à l'aide d'antagonistes de liaison à l'axe pd-1 et d'inhibiteurs de mek
    WO-2017087280-A1May 26, 2017Genentech, Inc., F. Hoffmann-La Roche AgProcédés de traitement d'un cancer positif her2
    WO-2017134302-A2August 10, 2017Orionis Biosciences Nv, Vib Vzw, Universiteit GentAgents thérapeutiques ciblés et leurs utilisations
    WO-2015033299-A1March 12, 2015Aurigene Discovery Technologies Limited1,2,4-oxadiazole derivatives as immunomodulators
    US-9212224-B2December 15, 2015Bristol-Myers Squibb CompanyAntibodies that bind PD-L1 and uses thereof
    WO-2017181111-A2October 19, 2017Genentech, Inc., F. Hoffmann-La Roche AgMéthodes de suivi et de traitement du cancer
    US-9856320-B2January 02, 2018Bristol-Myers Squibb CompanyCancer immunotherapy by disrupting PD-1/PD-L1 signaling
    WO-2016196381-A1December 08, 2016Genentech, Inc., F. Hoffmann La-Roche AgMéthylation de promoteur de pd-l1 dans le cancer
    WO-2017125532-A1July 27, 2017Innate PharmaNeutralisation des voies d'inhibition des lymphocytes
    US-9624298-B2April 18, 2017Merck Patent GmbhAnti-PD-L1 antibodies and uses thereof
    WO-2017075045-A3June 08, 2017Mayo Foundation For Medical Education And ResearchAntibodies to b7-h1
    WO-2017112741-A1June 29, 2017Novartis Ag, The Trustees Of The University Of Pennsylvania, Dana-Farber Cancer Institute, Inc., President And Fellows Of Harvard CollegeRécepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
    WO-2017058780-A1April 06, 2017Merck Patent Gmbh, Pfizer Inc.Combinaison d'un antagoniste de la liaison de l'axe pd-1 et d'un inhibiteur de alk dans le traitement du cancer alk-négatif
    WO-2017134305-A1August 10, 2017Orionis Biosciences Nv, Vib Vzw, Universiteit GentBispecific signaling agents and uses thereof
    EP-2854843-A4June 01, 2016Sorrento Therapeutics IncProtéines liant un antigène qui lient pd-l1
    JP-2016504336-AFebruary 12, 2016メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp., メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp.ヒトプログラム死リガンド1(pd−l1)に結合する抗体
    WO-2015036511-A1March 19, 2015F. Hoffmann-La Roche Ag, Hoffmann-La Roche Inc.Combination therapy of antibodies against human csf-1r and antibodies against human pd-l1
    WO-2017181079-A2October 19, 2017Genentech, Inc., F. Hoffmann-La Roche AgMéthodes de surveillance et de traitement du cancer
    WO-2017087851-A1May 26, 2017Genentech, Inc., F. Hoffmann-La Roche AgMethods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors
    DE-202014010421-U1November 12, 2015Kymab LimitedMenschliche Ziele
    WO-2015095423-A2June 25, 2015Genentech, Inc., F. Hoffmann-La Roche AgPolythérapie comprenant des agonistes se liant à ox40 et des antagonistes se liant à l'axe pd-1
    WO-2017064043-A1April 20, 2017Innate Pharma, Centre Léon BérardCd73 blocking agents
    US-9683048-B2June 20, 2017Novartis Ag, Dana-Farber Cancer Institute, Inc., President And Fellows Of Harvard CollegeAntibody molecules to PD-1 and uses thereof
    WO-2016111645-A1July 14, 2016Agency For Science, Technology And ResearchAnticorps anti-pd-l1
    WO-2015195163-A1December 23, 2015R-Pharm Overseas, Inc.Pd-l1 antagonist fully human antibody
    WO-2015187835-A2December 10, 2015Bristol-Myers Squibb CompanyAntibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
    WO-2016149201-A3November 24, 2016Cytomx Therapeutics, Inc.Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
    WO-2016007235-A1January 14, 2016Genentech, Inc., Spring Bioscience CorporationAnti-pd-l1 antibodies and diagnostic uses thereof
    WO-2016081384-A1May 26, 2016Genentech, Inc., F. Hoffmann-La Roche AgPolythérapie comprenant des agonistes se liant à ox40 et des antagonistes se liant à l'axe pd-1
    WO-2017055484-A1April 06, 2017INSERM (Institut National de la Santé et de la Recherche Médicale), Universite Nice Sophia Antipolis, Assistance Publique-Hôpitaux De Paris (Aphp)Methods for determining the metabolic status of lymphomas
    WO-2015112805-A1July 30, 2015Regeneron Pharmaceuticals, Inc.Anticorps humains dirigés contre pd-l1
    WO-2017144681-A1August 31, 2017Cell Medica Switzerland AgÉléments de liaison à pd-l1
    WO-2017151502-A1September 08, 2017Genentech, Inc., Foundation Medicine, Inc.Méthodes thérapeutiques et de diagnostic du cancer
    WO-2017159699-A1September 21, 2017Chugai Seiyaku Kabushiki Kaisha, Genentech, Inc.Procédés de traitement de cancers au moyen d'antagonistes se liant à l'axe pd-1 et d'anticorps anti-gpc3
    US-2015344577-A1December 03, 2015Dingfu Biotarget Co., LtdAgents for treating tumors, use and method thereof
    CN-104830788-AAugust 12, 2015杨光华DC cell based on HBV-HCV antigen, targeting immune cell population, preparation method and applications thereof
    WO-2014008218-A1January 09, 2014Bristol-Myers Squibb CompanyOptimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
    WO-2016200835-A1December 15, 2016Genentech, Inc.Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
    WO-2016146261-A1September 22, 2016Amal Therapeutics SaAssociation d'un modulateur de points de contrôle immunologiques et d'un complexe comprenant un peptide de pénétration cellulaire, un cargo et un agoniste des peptides tlr pour une utilisation en médecine
    WO-2016181349-A1November 17, 2016Pfizer Inc., Iteos TherapeuticsCombinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body
    JP-2015519375-AJuly 09, 2015ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc., ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc.Pd−l1に結合する抗原結合蛋白質
    US-9192667-B2November 24, 2015Hoffmann-La Roche Inc.Method of treating cancer by administering CSF-1R antibodies and a TLR9 agonist
    WO-2015042246-A1March 26, 2015Bristol-Myers Squibb CompanyCombinaison d'anticorps anti-lag-3 et d'anticorps anti-pd-1 pour traiter des tumeurs
    WO-2015033301-A1March 12, 2015Aurigene Discovery Technologies Limited1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
    WO-2016166348-A1October 20, 2016Elsalys Biotech, Centre National De La Recherche Scientifique, Institut CurieAnticorps anti-tyro3 et leurs utilisations
    EP-3178848-A1June 14, 2017F. Hoffmann-La Roche AGType ii anti-cd20 antibody for reducing formation of anti-drug antibodies
    WO-2017167921-A1October 05, 2017Centre Léon-BérardThérapie dictée par des lymphocytes exprimant cd73 chez un patient atteint de cancer
    WO-2017157964-A1September 21, 2017Amal Therapeutics SaAssociation d'un modulateur de points de contrôle immunologiques et d'un complexe comprenant un peptide de pénétration cellulaire, un cargo et un agoniste des peptides tlr pour une utilisation en médecine
    US-9776978-B2October 03, 2017Aurigene Discovery Technologies Limited1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
    WO-2016090300-A1June 09, 2016Genentech, Inc., F. Hoffmann-La Roche AgProcédés et compositions de traitement du cancer à l'aide d'antagonistes de l'axe pd-1 et d'antagonistes de hpk1
    WO-2017152085-A1September 08, 2017Bristol-Myers Squibb CompanyCombination therapy with anti-cd73 antibodies
    WO-2017077382-A1May 11, 2017Orionis Biosciences Nv, Vib Vzw, Universiteit GentBi-functional chimeric proteins and uses thereof